Single-Cell Omics

Single-Cell Omics Market Outlook

The global single-cell omics market is projected to reach USD 6.2 billion by 2035, growing at a compound annual growth rate (CAGR) of 16.9% during the forecast period from 2025 to 2035. This significant growth is fueled by the rising prevalence of chronic diseases, which necessitates advanced research methodologies to understand the complexities of cellular functions. Additionally, the increasing focus on personalized medicine and the growing investments in biotechnology and pharmaceutical sectors are further driving innovations in single-cell analysis technologies. The adoption of high-throughput sequencing technologies and the demand for targeted therapies are also contributing factors that are expected to propel the market forward. As research in genomics and proteomics continues to evolve, the single-cell omics market is becoming an essential component of modern biomedical research.

Growth Factor of the Market

The growth of the single-cell omics market can be attributed to several critical factors that are reshaping the landscape of biomedical research and diagnostics. One of the primary drivers is the increasing demand for precision medicine, which requires detailed insights into cellular heterogeneity and functionality. As a result, researchers are leveraging single-cell techniques to dissect complex tissues and understand the cellular microenvironments that contribute to disease progression. Furthermore, technological advancements in single-cell sequencing and analysis tools have made it easier and more cost-effective to conduct comprehensive studies of individual cells. These innovations are not only enhancing the throughput of experiments but are also improving the resolution of data, enabling researchers to capture rare cell populations and their distinct characteristics. Additionally, the growing prevalence of cancer and other chronic illnesses is prompting a surge in funding and resources allocated to single-cell research, driving further expansion in this market.

Key Highlights of the Market

• The market is expected to witness substantial growth due to increasing investments in research and development.
• Technological advancements in single-cell sequencing are enhancing the efficiency and accuracy of analyses.
• Rising prevalence of cancer and chronic diseases is driving the demand for single-cell omics technologies.
• Growing interest in personalized medicine is accentuating the importance of cellular-level insights.
• Collaborations between academic institutions and biopharmaceutical companies are fostering innovation and development in the field.

By Technology

Single-Cell Genomics:

Single-Cell Genomics is one of the key segments within the single-cell omics market that focuses on the genomic profiling of individual cells. This technology enables researchers to analyze genetic variations, mutations, and gene expression at an unprecedented resolution. By isolating and sequencing the genomes of single cells, scientists can uncover insights that are often masked when studying bulk populations. This method is particularly useful in cancer research, where heterogeneity among tumor cells can influence treatment outcomes. Moreover, advancements in microfluidics and next-generation sequencing technologies are continuously improving the efficiency and accuracy of single-cell genomic analyses, making them more accessible for researchers across disciplines.

Single-Cell Transcriptomics:

Single-Cell Transcriptomics is another pivotal technology that allows for the examination of gene expression profiles at the single-cell level. This technique provides insights into the dynamic changes in the transcriptome, which are essential for understanding cellular functions and responses to various stimuli. By analyzing the RNA content of individual cells, researchers can identify distinct cellular states, track lineage relationships, and explore processes such as differentiation and development. The integration of single-cell transcriptomics with other omics technologies is paving the way for a more holistic understanding of cellular behavior, particularly in complex diseases like neurological disorders and cancers.

Single-Cell Proteomics:

Single-Cell Proteomics focuses on the analysis of proteins within individual cells, offering insights into cellular functions that genomic and transcriptomic analyses may not capture. This technology is particularly beneficial for studying post-translational modifications and protein interactions, which play crucial roles in cellular signaling and disease mechanisms. As proteomics techniques continue to evolve, the ability to analyze proteins at the single-cell level has become increasingly important, especially in the context of immunology and cancer research. By revealing the protein landscape of individual cells, researchers can develop targeted therapies and diagnostic tools that are tailored to the specific molecular profiles of patients.

Single-Cell Epigenomics:

Single-Cell Epigenomics studies the epigenetic modifications that regulate gene expression without altering the DNA sequence itself. This segment is gaining traction as researchers seek to understand how epigenetic factors contribute to cellular diversity and disease processes. The ability to analyze methylation patterns and histone modifications at the single-cell level provides insights into developmental biology and cellular responses to environmental cues. With the advent of advanced sequencing technologies, the exploration of epigenetic landscapes is becoming more feasible, allowing for a deeper understanding of how epigenetic changes can influence cellular identity and function across various biological contexts.

Single-Cell Metabolomics:

Single-Cell Metabolomics is an emerging field that focuses on the analysis of metabolites within individual cells. This technology provides valuable insights into cellular metabolism and the biochemical processes that govern cellular behavior. Understanding the metabolomic profile of single cells can reveal how metabolic alterations are associated with diseases, such as cancer and diabetes. The ability to conduct metabolomic analyses on a single-cell scale allows researchers to identify metabolic heterogeneity within tissues, which is critical for understanding disease mechanisms and developing personalized therapeutic strategies. As analytical techniques improve, single-cell metabolomics is poised to play a significant role in advancing precision medicine.

By Application

Cancer Research:

Cancer Research is one of the most critical applications of single-cell omics technologies. By analyzing the heterogeneity of tumor cells at the single-cell level, researchers can gain insights into the genetic and molecular variations that drive cancer progression. This information is vital for developing targeted therapies and understanding mechanisms of drug resistance. Single-cell techniques allow for the identification of rare cell populations, such as cancer stem cells, which can significantly impact treatment outcomes. The ability to profile tumor microenvironments using single-cell analysis further enhances our understanding of cancer biology, facilitating the development of innovative therapeutic strategies.

Neurological Disorders:

Single-cell omics technologies are increasingly being applied to the study of neurological disorders. Understanding the cellular and molecular underpinnings of conditions such as Alzheimer's disease, Parkinson's disease, and schizophrenia requires detailed insights into the complex cell types present in neural tissues. Single-cell transcriptomics and proteomics enable researchers to unravel the cellular diversity and identify specific neuronal subtypes that may be implicated in disease processes. This application of single-cell technologies is pivotal for developing novel therapeutic targets and improving diagnostic accuracy in neurological conditions.

Stem Cell Research:

Stem Cell Research greatly benefits from single-cell omics, as these technologies allow for the characterization of stem cell populations and their differentiation pathways. By analyzing the transcriptomic and epigenomic profiles of individual stem cells, researchers can gain insights into the mechanisms governing stem cell fate decisions. This knowledge is essential for advancing regenerative medicine and developing therapies that harness the potential of stem cells for tissue repair and regeneration. The ability to monitor lineage tracing and differentiation at a single-cell resolution enhances our understanding of developmental biology and the therapeutic applications of stem cells.

Immunology:

In the field of Immunology, single-cell omics technologies are providing new insights into the complexities of the immune system. The ability to analyze immune cell populations at the single-cell level enables researchers to investigate cellular responses to pathogens, characterize immune cell subsets, and develop personalized immunotherapies. Single-cell transcriptomics and proteomics can reveal the functional states of immune cells, aiding in the understanding of autoimmune diseases and immune responses in cancer. This application is crucial for developing targeted therapies that can modulate immune responses effectively.

Developmental Biology:

Single-cell omics is transforming our understanding of Developmental Biology by providing insights into the cellular processes that govern development and differentiation. By studying individual cells at various stages of development, researchers can elucidate the molecular pathways that drive cell fate decisions and tissue formation. This knowledge is fundamental for understanding developmental disorders and congenital anomalies. The integration of single-cell technologies allows for the exploration of the dynamic changes that occur during embryogenesis and organogenesis, paving the way for advances in regenerative medicine and developmental therapeutics.

By User

Academic & Research Institutes:

Academic and research institutes are significant users of single-cell omics technologies, leveraging these advanced methodologies to explore complex biological questions. These institutions often drive innovation in the field, conducting foundational research that leads to new discoveries and applications. The ability to analyze single cells allows researchers to investigate cellular heterogeneity, lineage dynamics, and disease mechanisms in a detailed manner. Academic institutions also collaborate with industry partners to translate research findings into clinical applications, facilitating the development of novel therapeutics and diagnostics.

Biopharmaceutical Companies:

Biopharmaceutical companies are increasingly adopting single-cell omics technologies to enhance their drug development pipelines. These companies utilize single-cell analyses to identify novel drug targets, understand pharmacodynamics, and assess patient responses to therapies. By integrating single-cell data into their research workflows, biopharmaceutical firms can develop more effective and personalized treatment options. The ability to study tumor heterogeneity and the immune microenvironment at the single-cell level is particularly relevant for oncology and immunotherapy applications. As a result, the biopharmaceutical sector is a key driver of growth in the single-cell omics market.

Hospitals & Diagnostic Laboratories:

Hospitals and diagnostic laboratories are beginning to incorporate single-cell omics technologies into their clinical workflows to improve diagnostics and patient care. The ability to analyze individual cells can enhance the detection of rare disease-related cell types, enabling earlier and more accurate diagnoses. Additionally, single-cell analyses can provide insights into tumor profiling and treatment stratification, allowing for more effective personalized medicine approaches. As the importance of precision medicine grows, hospitals and diagnostic labs are increasingly investing in single-cell technologies to meet the evolving needs of patients and healthcare providers.

By Cell Type

Stem Cells:

Stem Cells represent a crucial area of focus within the single-cell omics market, as these cells hold significant promise for regenerative medicine and therapeutic applications. Analyzing stem cells at the single-cell level enables researchers to understand their unique properties, differentiation pathways, and potential for tissue regeneration. Single-cell transcriptomics and epigenomics are particularly valuable for characterizing stem cell populations and uncovering the mechanisms that govern their behavior. This understanding is essential for developing stem cell-based therapies and optimizing protocols for stem cell manipulation and expansion.

Cancer Cells:

Cancer Cells are a primary target for single-cell omics research, as understanding their heterogeneity is critical for improving cancer diagnostics and therapeutics. Single-cell techniques allow researchers to dissect the genetic and phenotypic variations within tumors, identifying unique subpopulations that may respond differently to therapies. By analyzing cancer cells at the single-cell level, scientists can uncover biomarkers associated with drug resistance and metastasis, leading to the development of targeted treatment strategies. This application is vital for advancing precision oncology and developing more effective therapeutic options for cancer patients.

Immune Cells:

Immune Cells are another significant focus of single-cell omics research, as these cells play a central role in the body’s defense mechanisms and disease processes. Single-cell analyses enable researchers to characterize the functional states and heterogeneity of immune cell populations, providing insights into immune responses to infections, cancers, and autoimmune disorders. By profiling immune cells at the single-cell level, scientists can identify novel therapeutic targets and develop personalized immunotherapies. This application is particularly relevant in the context of vaccine development and understanding the immune landscape in various diseases.

Neuronal Cells:

Neuronal Cells are increasingly being studied using single-cell omics technologies to unravel the complexities of the nervous system. By analyzing individual neurons, researchers can gain insights into neuronal diversity, connectivity, and functional properties. This information is crucial for understanding neurological disorders and developing targeted therapies for conditions such as Alzheimer's disease and autism spectrum disorders. Single-cell transcriptomics and proteomics are instrumental in identifying specific neuronal subtypes and elucidating their roles in brain function, paving the way for advances in neurotherapeutics and regenerative medicine.

Epithelial Cells:

Epithelial Cells are essential components of various tissues and organs, and their study through single-cell omics provides valuable insights into tissue homeostasis and pathology. By analyzing epithelial cells at the single-cell level, researchers can investigate cellular responses to environmental changes, disease states, and therapeutic interventions. This application is particularly relevant in cancer research, where epithelial cell heterogeneity can influence tumor behavior and treatment outcomes. Single-cell techniques enable the characterization of epithelial cell populations and their interactions within the tissue microenvironment, contributing to the understanding of epithelial biology and disease mechanisms.

By Region

In North America, the single-cell omics market is expected to dominate the global landscape, driven by robust investments in biotechnology and pharmaceutical research. The region is home to several leading academic institutions and biopharmaceutical companies, which are at the forefront of single-cell research. The increasing prevalence of chronic diseases, coupled with a growing emphasis on precision medicine, is further fueling market growth in this region. North America is projected to account for approximately 45% of the global single-cell omics market by 2035, with a CAGR of 17.5% during the forecast period. Additionally, advancements in single-cell sequencing technologies and collaborations between academia and industry are enhancing the region's competitive position in the market.

In Europe, the single-cell omics market is also experiencing significant growth, with a focus on research and development initiatives supported by government funding and academic collaborations. The region is witnessing a rising demand for innovative diagnostics and therapies driven by an aging population and the increasing burden of chronic diseases. Europe is expected to capture around 30% of the global market share by 2035. The Asia Pacific region is emerging as a lucrative market for single-cell omics, with rapid advancements in biotechnology and increasing investments in research infrastructure. The growing prevalence of cancer and other chronic diseases in countries like China and India is expected to drive market expansion, contributing approximately 20% to the global market share by 2035. Latin America and the Middle East & Africa are projected to account for the remaining share, driven by rising research activities and partnerships in the healthcare sector.

Opportunities

The single-cell omics market is poised to capitalize on several emerging opportunities as advancements in technology and research continue to unfold. One of the most promising opportunities lies in the integration of single-cell omics with artificial intelligence (AI) and machine learning. These technologies can enhance data analysis capabilities, enabling researchers to derive deeper insights from complex single-cell datasets. By employing AI-driven algorithms to identify patterns and correlations within single-cell data, researchers can accelerate the discovery of novel biomarkers and therapeutic targets. This convergence of technologies has the potential to revolutionize the field of precision medicine, ultimately leading to more effective treatments and improved patient outcomes. Additionally, the increasing availability of public genomic databases and collaborative research initiatives can further drive innovation and knowledge-sharing within the single-cell omics community.

Another significant opportunity for growth in the single-cell omics market is the rising interest in personalized medicine and targeted therapies. As the healthcare landscape shifts towards more individualized treatment approaches, the demand for technologies that can provide comprehensive insights into cellular heterogeneity will continue to grow. Researchers and clinicians require robust tools to understand patient-specific disease mechanisms and tailor therapies accordingly. The ability to profile single cells and characterize their unique molecular signatures will be essential in developing personalized treatment regimens for various conditions, including cancer, autoimmune diseases, and genetic disorders. As the market evolves, companies that focus on developing user-friendly, high-throughput single-cell platforms will likely capture significant market share, meeting the demands of researchers and clinicians alike.

Threats

Despite the promising growth prospects, the single-cell omics market faces several threats that could hinder its expansion. One of the primary concerns is the high cost associated with single-cell technologies and the specialized equipment needed for analysis. This financial barrier may limit access for some research institutions, particularly in developing regions, thereby restricting the overall market growth. Additionally, the complexity of single-cell analyses and the need for advanced bioinformatics capabilities can pose challenges for researchers, particularly those who may lack the necessary expertise or infrastructure. As the market continues to evolve, addressing these challenges will be essential to ensure widespread adoption and utilization of single-cell omics technologies.

Another significant threat to the single-cell omics market is the rapid pace of technological advancements, which can lead to obsolescence of existing products and platforms. As new methodologies and technologies emerge, companies must continuously innovate to remain competitive. This pressure to stay ahead of the curve can strain resources and impact profitability for smaller firms or startups in the field. Furthermore, the increasing complexity of regulatory requirements for genetic and genomic research may pose additional challenges, particularly for companies operating in heavily regulated markets. Ensuring compliance with these regulations while navigating the rapidly changing landscape of single-cell technologies will be crucial for sustaining growth and maintaining competitive advantage.

Competitor Outlook

• 10x Genomics
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• BD Biosciences
• Merck KGaA
• Fluidigm Corporation
• Mission Bio, Inc.
• Gentueri, Inc.
• Parse Biosciences, Inc.
• Singleron Biotechnologies
• Cell Signaling Technology, Inc.
• STEMCELL Technologies Inc.
• Zymergen Inc.
• Takara Bio Inc.

The competitive landscape of the single-cell omics market is characterized by the presence of established players, emerging startups, and academic partnerships, all contributing to the rapid innovation and growth in the sector. Companies such as 10x Genomics and Illumina, Inc. are leading the charge with their advanced single-cell sequencing platforms and technologies. These firms have developed comprehensive solutions that enable researchers to conduct high-throughput single-cell analyses with ease, significantly enhancing the accessibility and utility of single-cell omics. As competition intensifies, companies are increasingly focusing on collaborations, mergers, and acquisitions to bolster their product offerings and expand their market reach. Strategic partnerships between academic institutions and commercial entities are also becoming more common, facilitating the translation of cutting-edge research into practical applications.

In addition to the leading players, numerous emerging companies are entering the single-cell omics market, bringing innovative technologies and solutions to the forefront. For instance, Mission Bio, Inc. is known for its pioneering work in single-cell DNA analysis, offering unique platforms that enable researchers to explore genetic variations at the single-cell level. Similarly, Parse Biosciences, Inc. is making strides in developing user-friendly single-cell RNA sequencing technologies that cater to a wide range of research applications. These startups are driving innovation and competition in the market, challenging established players to continuously enhance their offerings and adapt to the evolving needs of researchers.

The presence of diverse players in the single-cell omics market fosters a dynamic ecosystem where innovation thrives. Major companies are investing heavily in research and development to create next-generation technologies that improve sensitivity, resolution, and throughput. For example, Thermo Fisher Scientific, Inc. is actively developing integrated platforms that combine single-cell isolation, sequencing, and analysis to streamline workflows and provide comprehensive insights into cellular functions. Additionally, BD Biosciences and Bio-Rad Laboratories, Inc. are expanding their portfolios to include advanced reagents and tools that enhance the capabilities of single-cell omics technologies. This competitive landscape is set to evolve further as the demand for single-cell insights continues to grow, leading to new opportunities for collaboration, innovation, and advancements in the field.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 10x Genomics
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Zymergen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 BD Biosciences
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Gentueri, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Illumina, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Takara Bio Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Mission Bio, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Fluidigm Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Parse Biosciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Singleron Biotechnologies
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bio-Rad Laboratories, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 STEMCELL Technologies Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Cell Signaling Technology, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Single-Cell Omics Market, By User
    • 6.1.1 Academic & Research Institutes
    • 6.1.2 Biopharmaceutical Companies
    • 6.1.3 Hospitals & Diagnostic Laboratories
  • 6.2 Single-Cell Omics Market, By Cell Type
    • 6.2.1 Stem Cells
    • 6.2.2 Cancer Cells
    • 6.2.3 Immune Cells
    • 6.2.4 Neuronal Cells
    • 6.2.5 Epithelial Cells
  • 6.3 Single-Cell Omics Market, By Technology
    • 6.3.1 Single-Cell Genomics
    • 6.3.2 Single-Cell Transcriptomics
    • 6.3.3 Single-Cell Proteomics
    • 6.3.4 Single-Cell Epigenomics
    • 6.3.5 Single-Cell Metabolomics
  • 6.4 Single-Cell Omics Market, By Application
    • 6.4.1 Cancer Research
    • 6.4.2 Neurological Disorders
    • 6.4.3 Stem Cell Research
    • 6.4.4 Immunology
    • 6.4.5 Developmental Biology

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Single-Cell Omics Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Single-Cell Omics market is categorized based on

By Technology

• Single-Cell Genomics
• Single-Cell Transcriptomics
• Single-Cell Proteomics
• Single-Cell Epigenomics
• Single-Cell Metabolomics

By Application

• Cancer Research
• Neurological Disorders
• Stem Cell Research
• Immunology
• Developmental Biology

By User

• Academic & Research Institutes
• Biopharmaceutical Companies
• Hospitals & Diagnostic Laboratories

By Cell Type

• Stem Cells
• Cancer Cells
• Immune Cells
• Neuronal Cells
• Epithelial Cells

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• 10x Genomics
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• BD Biosciences
• Merck KGaA
• Fluidigm Corporation
• Mission Bio, Inc.
• Gentueri, Inc.
• Parse Biosciences, Inc.
• Singleron Biotechnologies
• Cell Signaling Technology, Inc.
• STEMCELL Technologies Inc.
• Zymergen Inc.
• Takara Bio Inc.